<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397175</url>
  </required_header>
  <id_info>
    <org_study_id>CHOICE</org_study_id>
    <nct_id>NCT01397175</nct_id>
  </id_info>
  <brief_title>BES, EES, and ZES-R in Real World Practice</brief_title>
  <acronym>CHOICE</acronym>
  <official_title>A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gangwon Cardiovascular Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the rate of device-oriented composite
      consisted of cardiac death, myocardial infarction not clearly attributable to a nontarget
      vessel, and clinically indicated target lesion revascularization among the patients treated
      with EES, ZES-R, or BES at 24-month clinical follow-up post-index procedure. Trial end points
      are summarized in Table I. The hypothesis is that BES is equivalent to EES or BES is
      equivalent to ZES-R at the primary end point.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous randomized trials have shown the superior efficacy of drug-eluting stents (DES),
      such as sirolimus-eluting stent (SES, CYPHER, Cordis, US), paclitaxel-eluting stent (PES,
      TAXUS, Boston Scientific, US), and zotarolimus-eluting stent (ZES, Endeavor, Medtronic, US)
      compared with bare metal stents (BMS) by reducing neointimal hyperplasia, late luminal loss,
      and angiographic restenosis leading to decreased target lesion revascularization.
      Unfortunately, restenosis still occurs and late stent thrombosis can develop by delaying
      endoluminal healing or by chronic inflammation.Accordingly, development of new DES is
      required to improve efficacy by reducing revascularization and safety by reducing the risk of
      stent thrombosis. With the improvement of polymer, drug, and the platform, the 2nd generation
      DES, including everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA),
      zotarolimus-eluting stent with biolinx polymer (ZES-R, Endeavor Resolute or Endeavor Resolute
      Integrity, Medtronic, USA), and biolimus-eluting stent (BES, BioMatrix or Biomatrix Flex,
      Biosensors, USA), have been shown to be superior or non-inferior in safety and efficacy
      trials compared with 1st generation DES.

      However, it is difficult to know if there are any differences in efficacy and safety between
      the EES, the ZES-R, and the BES, in real world practice due to the lack of data comparing
      these three 2nd generation DES directly. This study provides the evidence for the CHOICE of
      stent when physicians are treating patients by percutaneous coronary intervention.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-oriented composite</measure>
    <time_frame>24 months</time_frame>
    <description>Device-oriented composite consisted of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target lesion revascularization (TLR) at 24-month clinical follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite</measure>
    <time_frame>at 24 months</time_frame>
    <description>Patient-oriented composite consisted of all-cause mortality, any myocardial infarction, and any revascularization at 24-month clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-oriented composite</measure>
    <time_frame>12 months</time_frame>
    <description>Device-oriented composite at 12-month clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite</measure>
    <time_frame>12 months</time_frame>
    <description>Patient-oriented composite at 12-month clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each component of device- and patient-oriented composite</measure>
    <time_frame>12 months</time_frame>
    <description>Each component of device- and patient-oriented composite at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each component of device- and patient-oriented composite</measure>
    <time_frame>24 months</time_frame>
    <description>Each component of device- and patient-oriented composite at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>ARC defined stent thrombosis at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>24 months</time_frame>
    <description>ARC defined stent thrombosis at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>ARC defined stent thrombosis at 12 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>24 months</time_frame>
    <description>ARC defined stent thrombosis at 24 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications defined by BARC definition</measure>
    <time_frame>before discharge</time_frame>
    <description>Bleeding complications defined by BARC definition before discharge</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1960</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Biolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zotarolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biolimus-eluting stent</intervention_name>
    <description>Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.</description>
    <arm_group_label>Biolimus-eluting stent</arm_group_label>
    <other_name>Biomatrix, Biosensors, USA</other_name>
    <other_name>Biomatrix flex, Biosensors, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent</intervention_name>
    <description>Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.</description>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <other_name>Xience V, Abbott, USA</other_name>
    <other_name>Xience Prime, Abbott, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-eluting stent</intervention_name>
    <description>Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.</description>
    <arm_group_label>Zotarolimus-eluting stent</arm_group_label>
    <other_name>Endeavor Resolute, Medtronic, USA</other_name>
    <other_name>Endeavor Resolute Integrity, Medtronic, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age &gt; 19 years

          -  Subject is able to verbally confirm understanding of risks, benefits and treatment
             alternatives of receiving the drug-eluting stent(s) and he/she or his/her legally
             authorized representative provides written informed consent prior to any study related
             procedure

          -  Subject must have significant stenosis (&gt;50% by visual estimate) on a native or
             in-stent coronary artery

          -  Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,
             recent infarction, acute myocardial infarction, positive functional study or a
             reversible changes in the ECG consistent with ischemia). In subjects with coronary
             artery stenosis &gt;75%, evidence of myocardial ischemia does not have to be documented

        Exclusion Criteria

          -  Subject has a known hypersensitivity or contraindication to any of the following
             medications: heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9,
             everolimus, zotarolimus, stainless steel, cobalt chromium, contrast media (Patients
             with documented sensitivity to contrast media, which can be effectively premedicated
             with steroid and diphenhydramine may be enrolled. However, those with true anaphylaxis
             to prior contrast media should not be enrolled.)

          -  Subject in use of systemic (intravenous) biolimus A9, everolimus or zotarolimus within
             12 months.

          -  Female subject of childbearing potential, unless a recent pregnancy test is negative,
             who possibly plans to become pregnant any time after enrollment into this study

          -  Subject planned an elective surgical procedure that would necessitate interruption of
             antiplatelet during the first 12 months post enrollment

          -  Subject with non-cardiac co-morbid condition with life expectancy &lt; 2 year or that may
             result in protocol non-compliance (per site investigator's medical judgment)

          -  Subject with cardiogenic shock at presentation

          -  Subject who are actively participating in another drug or device investigational
             study, who have not completed the primary end point follow-up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Chrisitian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncheon St. Carollo Hospital</name>
      <address>
        <city>Suncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006 May 16;113(19):2293-300. Epub 2006 May 8.</citation>
    <PMID>16682614</PMID>
  </reference>
  <reference>
    <citation>Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.</citation>
    <PMID>14523139</PMID>
  </reference>
  <reference>
    <citation>Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.</citation>
    <PMID>17174201</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 Jan 15;350(3):221-31.</citation>
    <PMID>14724301</PMID>
  </reference>
  <reference>
    <citation>Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, Popma JJ, Serruys PW, Kimura T, Williams DO, Windecker S, Krucoff MW. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007 Jul 10;50(2):109-18. Epub 2007 May 22. Review.</citation>
    <PMID>17616294</PMID>
  </reference>
  <reference>
    <citation>Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 May 4;293(17):2126-30.</citation>
    <PMID>15870416</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001 Apr 17;103(15):1967-71.</citation>
    <PMID>11306525</PMID>
  </reference>
  <reference>
    <citation>Doyle B, Rihal CS, O'Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, Bresnahan J, Holmes DR Jr. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007 Nov 20;116(21):2391-8. Epub 2007 Nov 5.</citation>
    <PMID>17984377</PMID>
  </reference>
  <reference>
    <citation>Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007 Feb 24;369(9562):667-78.</citation>
    <PMID>17321312</PMID>
  </reference>
  <reference>
    <citation>Roukoz H, Bavry AA, Sarkees ML, Mood GR, Kumbhani DJ, Rabbat MG, Bhatt DL. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med. 2009 Jun;122(6):581.e1-10. doi: 10.1016/j.amjmed.2008.12.019.</citation>
    <PMID>19486720</PMID>
  </reference>
  <reference>
    <citation>Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009 Jun 30;119(25):3198-206. doi: 10.1161/CIRCULATIONAHA.108.826479. Epub 2009 Jun 15.</citation>
    <PMID>19528338</PMID>
  </reference>
  <reference>
    <citation>Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9. Epub 2007 Feb 12.</citation>
    <PMID>17296821</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 Mar 8;356(10):998-1008. Epub 2007 Feb 12.</citation>
    <PMID>17296824</PMID>
  </reference>
  <reference>
    <citation>Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW; SPIRIT II and III Investigators. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc Interv. 2010 Dec;3(12):1220-8. doi: 10.1016/j.jcin.2010.07.017.</citation>
    <PMID>21232715</PMID>
  </reference>
  <reference>
    <citation>Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010 Jan 16;375(9710):201-9. doi: 10.1016/S0140-6736(09)62127-9. Epub 2010 Jan 7.</citation>
    <PMID>20060578</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13. doi: 10.1001/jama.299.16.1903.</citation>
    <PMID>18430909</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ; SPIRIT IV Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011 Jun 28;58(1):19-25. doi: 10.1016/j.jacc.2011.02.022. Epub 2011 Apr 21.</citation>
    <PMID>21514084</PMID>
  </reference>
  <reference>
    <citation>Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010 Jul 8;363(2):136-46. doi: 10.1056/NEJMoa1004130. Epub 2010 Jun 16.</citation>
    <PMID>20554978</PMID>
  </reference>
  <reference>
    <citation>Silber S, Windecker S, Vranckx P, Serruys PW; RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011 Apr 9;377(9773):1241-7. doi: 10.1016/S0140-6736(11)60395-4. Epub 2011 Apr 1.</citation>
    <PMID>21459430</PMID>
  </reference>
  <reference>
    <citation>Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011 Dec 3;378(9807):1940-8. doi: 10.1016/S0140-6736(11)61672-3. Epub 2011 Nov 8.</citation>
    <PMID>22075451</PMID>
  </reference>
  <reference>
    <citation>Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008 Sep 27;372(9644):1163-73. doi: 10.1016/S0140-6736(08)61244-1. Epub 2008 Aug 31.</citation>
    <PMID>18765162</PMID>
  </reference>
  <reference>
    <citation>Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007 Feb 27;115(8):1051-8. Review.</citation>
    <PMID>17325255</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Yoon Junghan</investigator_full_name>
    <investigator_title>Professor of Cardiology, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Drug-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

